Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Maze Therapeutics, Inc.NASDAQ: MAZE
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $42.36M fell 66.7% year over year, behind the -2.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 1079.9% from the prior quarter. Over 3 fiscal years it compounded at +442.1% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -66.7% toward the trailing-twelve-month pace of -2.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 275.34M USD
- Year-over-year change
- +196.5%
- 3-year CAGR
- +442.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 275.34M | +196.5% |
| FY2024 | 2024-12-31 | 92.85M | +466.7% |
| FY2023 | 2023-12-31 | 16.39M | +848.2% |
| FY2022 | 2022-12-31 | 1.73M | — |
Financing Cash Flow vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.7% is the 6th highest of 8, against a peer median of +59.4%.
- Financing cash flow amounts to 951.6% of revenue for MAZE, versus a peer median of 68.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $536M USD | +2312.8% | +25.4% | 53.1% | |
| LTM Sep 2026 | $245.69M USD | +211.1% | — | 37.7% | |
| FY2025 | €232M EUR | +59.4% | +84.0% | 5175.1% | |
| LTM Mar 2026 | $190.32M USD | -2.7% | +442.1% | 951.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $136.68M USD | -35.4% | +66.2% | 1325.0% |
SEPNSepterna, Inc. | LTM Sep 2026 | $80.93M USD | -73.5% | -61.7% | 84.1% |
| LTM Mar 2026 | $58.47M USD | +6.1% | -10.2% | 13.7% | |
| LTM Mar 2026 | $44.68M USD | +269.7% | — | — | |
| Peer median (excluding MAZE) | — | +59.4% | +25.4% | 68.6% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.